Close Menu

This article has been updated to include information about an FDA-approved companion diagnostic for pralsetinib.

NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to Blueprint Medicines and Genentech's Gavreto (pralsetinib) for metastatic, RET fusion-positive, non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.